Medpage Today on MSN
Another Sleep Apnea Drug May Be on the Horizon for a Broader Population
CHICAGO -- A novel combination drug targeting neuromuscular dysfunction in obstructive sleep apnea (OSA) reduced severity of ...
Adults with mild to severe obstructive sleep apnea achieved lower disease severity with AD109, an oral combination drug, at ...
A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. In ...
VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 ...
Prevalent cases of pulmonary NTM are expected to increase by 7.2% in the seven major pharmaceutical markets between 2023 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback